135782-29-5

Usage

Uses

Used in Pharmaceutical Industry:
4-(Phenylmethyl)-2-morpholinecarboxylic acid methyl ester is used as a key intermediate in the synthesis of 4-sulfonylmorpholine derivatives. These derivatives are known to be potent inhibitors of human 11-β-hydroxy steroid dehydrogenase type 1 (11β-HSD1), an enzyme that plays a crucial role in the regulation of glucocorticoid hormones. Inhibition of this enzyme has been linked to the treatment of various metabolic disorders, such as type 2 diabetes, obesity, and hypertension.
The application of 4-(Phenylmethyl)-2-morpholinecarboxylic acid methyl ester in the pharmaceutical industry is primarily due to its ability to serve as a building block for the development of novel 11β-HSD1 inhibitors. These inhibitors can potentially be used as therapeutic agents for the treatment of metabolic diseases by modulating the levels of glucocorticoids in the body.

Upstream product

• 147767-51-9 4-benzyl-2-cyanomorpholine 
• 104-63-2 N-Benzylethanolamine 
• 67-56-1 methanol 
• 135072-15-0 4-benzylmorpholine-2-carboxylic acid hydrochloride 

Downstream Products

• 500789-41-3 4-(t-butyloxycarbonyl)morpholine-2-carboxylic acid methyl ester 
• 1030837-49-0 (S)-4-benzyl-morpholine-2-carboxylic acid 
• 1401233-92-8 (R)-4-benzylmorpholine-2-carboxyester 
• 1401233-93-9 (R)-4-benzylmorpholine-2-carboxylic acid hydrochloride 

Relevant academic research and scientific papers

A COMPOUND FOR INHIBITING HUMAN 11-β-HYDROXY STEROID DEHYDROGENASE TYPE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

The present invention relates to a novel compound, or a stereoisomer, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition for human-11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) comprising the same. The invention provides a compound, which has excellent activity and solubility and is more efficiently formulated and delivered, and a pharmaceutical composition for human-11-beta-hydroxysteroid dehydrogenase type 1 comprising the same.

NOVEL CYCLIC AMINOBENZOIC ACID DERIVATIVE

The present invention relates to cyclic amino benzoic acid derivatives which are effective in therapy of lipid metabolism abnormality, diabetes and the like as a human peroxisome proliferators-activated receptor (PPAR) agonist, in particular, as an agonist against human PPARα isoform, and addition salts thereof, and pharmaceutical compositions containing these compounds. A cyclic amino benzoic acid derivative represented by the general formula (1) [wherein a ring Ar represents an aryl group which may have substituent, or the like; Y represents a C1-C4 alkylene, C2-C4 alkenylene, C2-C4 alkynylene, or the like; Z represents an oxygen atom, sulfur atom or - (CH2)n- (n represents 0,1 or 2) ; X represents a hydrogen atom, halogen atom, lower alkyl group which may be substituted with a halogen atom, or the like; R represents a hydrogen atom or lower alkyl group, and -COOR substitutes for an ortho position or metha position of binding position of ring W] or a pharmaceutically acceptable salt thereof.